SPRB · Insider Trading
Spruce Biosciences, Inc. Common Stock
Every open-market purchase and sale reported by SPRB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-29 | Adrian W Quartel | Chief Medical Officer | A | — | — |
| 2026-07-09 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2026-05-26 | MICHAEL G GREY | Executive Chairman | A | — | — |
| 2026-05-26 | Percival Barretto-Ko | Director | A | — | — |
| 2026-05-26 | CAMILLA V SIMPSON | Director | A | — | — |
| 2026-05-26 | Keli Walbert | Director | A | — | — |
| 2026-05-26 | DANIEL K SPIEGELMAN | Director | A | — | — |
| 2026-03-09 | Corwin Dale Hooks | Chief Commercial Officer | A | — | — |
| 2026-01-21 | Douglas Kirk Ways | Interim Chief Medical Officer | M | — | — |
| 2026-01-05 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-12-17 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | — | — |
| 2025-12-17 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-12-15 | Keli Walbert | Director | A | — | — |
| 2025-12-15 | Percival Barretto-Ko | Director | MIXED | — | — |
| 2025-12-15 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-12-15 | MICHAEL G GREY | Executive Chairman | MIXED | — | — |
| 2025-12-15 | DANIEL K SPIEGELMAN | Director | MIXED | — | — |
| 2025-12-15 | CAMILLA V SIMPSON | Director | MIXED | — | — |
| 2025-12-15 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | — | — |
| 2025-12-12 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-12-12 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | — | — |
| 2025-10-22 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2025-10-22 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | — | — |
| 2025-10-15 | Gregory Martinez | 10%+ Owner | MIXED | — | — |
| 2025-10-08 | Parkman Healthcare Partners LLC | 10%+ Owner | MIXED | — | — |
| 2025-07-24 | Bali Muralidhar | Director | A | — | — |
| 2025-07-24 | CAMILLA V SIMPSON | Director | A | — | — |
| 2025-07-24 | Tiba Aynechi | Director | A | — | — |
| 2025-07-24 | Kirk Ways | Interim Chief Medical Officer | A | — | — |
| 2025-07-24 | Percival Barretto-Ko | Director | A | — | — |
| 2025-07-24 | DANIEL K SPIEGELMAN | Director | A | — | — |
| 2025-07-24 | MICHAEL G GREY | Executive Chairman | A | — | — |
| 2024-12-20 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | MIXED | — | — |
| 2024-12-20 | Ralph William Charlton III | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2024-12-20 | Samir M. Gharib | PRESIDENT AND CFO | MIXED | — | — |
| 2024-05-24 | DANIEL K SPIEGELMAN | Director | A | — | — |
| 2024-05-24 | CAMILLA V SIMPSON | Director | A | — | — |
| 2024-05-24 | MICHAEL G GREY | Executive Chairman | A | — | — |
| 2024-05-24 | Bali Muralidhar | Director | A | — | — |
| 2024-05-24 | Tiba Aynechi | Director | A | — | — |
| 2024-05-24 | Kirk Ways | Director | A | — | — |
| 2024-05-24 | Percival Barretto-Ko | Director | A | — | — |
| 2024-03-25 | Novo Holdings A/S | 10%+ Owner | Sell | — | — |
| 2024-03-20 | Novo Holdings A/S | 10%+ Owner | Sell | — | — |
| 2024-03-18 | Samir M. Gharib | PRESIDENT AND CFO | A | — | — |
| 2024-03-18 | Javier B. Szwarcberg | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-03-18 | Ralph William Charlton III | CHIEF MEDICAL OFFICER | A | — | — |
| 2024-03-18 | Novo Holdings A/S | 10%+ Owner | Sell | — | — |
| 2024-01-03 | Ralph William Charlton III | Chief Medical Officer | A | — | — |
| 2024-01-03 | Samir M. Gharib | President & CFO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 34,000 | — |
| — | Director | 28,814 | — |
| — | 10%+ Owner | 28,814 | — |
| — | 10%+ Owner | 28,644 | — |
| — | — | 27,115 | — |
| — | Director | 27,115 | — |
| — | Director | 21,234 | — |
| — | CHIEF EXECUTIVE OFFICER | 19,270 | — |
| — | Director | 17,684 | — |
| — | PRESIDENT AND CFO | 7,934 | — |
| — | CHIEF MEDICAL OFFICER | 2,005 | — |
| — | Interim Chief Medical Officer | 1,250 | — |
| — | 10%+ Owner | 1,075 | — |
| — | 10%+ Owner | 1,050 | — |
| — | Chief Executive Officer | 30 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPRB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.